Table II.
ELISA manufacturer information and associated CVs for each of the studies
| Study | ELISA manufacture information |
Type of ELISA |
Specific antibodies used |
Interassay CV | Intraassay CV |
|---|---|---|---|---|---|
| Cibere et al.14 | AnaMar Medical, Lund, Sweden | Sandwich | Two monoclonal antibodies (not specified) | <5% | <5% |
| Clark et al.4 | In house method* | Competitive | Monoclonal antibody 17-C10 | Not reported | Not reported |
| Fernandeset al.3 | Anamar Medical, Uppsala, Sweden | Sandwich | Two monoclonal antibodies (not specified) | Not reported | Not reported |
| Jordan et al.23 | In house method* | Sandwich | Monoclonal antibodies 16-F12 and 17-C10 | 9.7% for “normal” controls 8.7% for “high” controls | 5.8% for “normal” controls 6.6% for “high” controls |
| Mundermannet al.33 | AnaMar Medical AB, Lund, Sweden | Sandwich | Mouse monoclonal antibodies (not specified) | <1.9% | <2.7% |
| Senolt et al.11 | In house method* | Sandwich | Monoclonal antibodies 17-C10 and 16-F12 | Not reported | Not reported |
| Wakitani et al.12 | Kamiya Biomedical Company, Seattle, WA. | Sandwich | Not specified | Not reported | Not reported |
*
The same in house method was used for each of these studies, and the information regarding this method can be found in Vilim V, Voburka Z, Vytasek R, Senolt L, Tchetverikoc I, Kraus VB, et al. Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA. Clin Chim Acta 2003;328:59–69. However, it must be noted that Clark et al.4 and Jordan et al.23 reported slight modifications to the in house method used for their studies.